RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)

被引：9

作者：

Tabernero, Josep

Cohn, Allen Lee

Obermannova, Radka

Bodoky, Gyorgy

Garcia-Carbonero, Rocio

Ciuleanu, Tudor-Eliade

Portnoy, David Craig

Van Cutsem, Eric

Grothey, Axel

Prausova, Jana

Garcia-Alfonso, Pilar

Yamazaki, Kentaro

Clingan, Philip R.

Zagonel, Vittorina

Kim, Tae Won

Simms, Lorinda

Chang, Shao-Chun

Nasroulah, Federico

Yoshino, Takayuki

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] US Oncol, Rocky Mt Canc Ctr, Denver, CO USA

[3] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic

[4] Szent Laszlo Hosp, Budapest, Hungary

[5] Hosp Virgen del Rocio, Seville, Spain

[6] Prof Dr I Chiricuta Inst Oncol, Cluj Napoca, Cluj County, Romania

[7] West Clin, Memphis, TN USA

[8] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

[9] Mayo Clin, Rochester, MN USA

[10] Univ Hosp Motol, Prague, Czech Republic

[11] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[12] Shizuoka Canc Ctr, Shizuoka, Japan

[13] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[14] IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy

[15] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[16] Eli Lilly Canada Inc, Toronto, ON, Canada

[17] Eli Lilly & Co, Indianapolis, IN 46285 USA

[18] Eli Lilly & Co, Bridgewater, NJ USA

[19] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.512

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

512

引用

页数：1